微电生理(688351) - 2025 Q2 - 季度业绩预告

Current Period Performance Forecast (2025 H1) The company forecasts 2025 H1 operating revenue between RMB 215 million and RMB 230 million, with net profit attributable to shareholders ranging from RMB 30 million to RMB 35 million, indicating substantial growth 2025 H1 Performance Forecast | Metric | Estimated Amount (RMB) | Year-on-Year Growth Rate (%) | | :--- | :--- | :--- | | Operating Revenue | 215.00 million - 230.00 million | 8.39 - 15.95 | | Net Profit Attributable to Shareholders | 30.00 million - 35.00 million | 76.34 - 105.73 | - The data contained in this performance forecast has not been audited by a certified public accountant[4] Prior Period Performance (2024 H1) In 2024 H1, the company reported operating revenue of RMB 198.36 million and net profit attributable to shareholders of RMB 17.01 million 2024 H1 Performance Overview | Metric | Amount (RMB) | | :--- | :--- | | Operating Revenue | 198.3646 million | | Net Profit Attributable to Shareholders | 17.0127 million | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 0.9217 million | | Total Profit | 17.0327 million | | Earnings Per Share | 0.0362 | Analysis of Performance Changes Performance growth is primarily driven by the company's focus on cardiac electrophysiology, strong overseas sales, and successful new product launches - The company's core strategy focuses on deep cultivation in the cardiac electrophysiology field, driven by globalization, leveraging a product matrix across 'ice, fire, electricity, and magnetic' technical pathways, primarily targeting the atrial fibrillation treatment market[8] - Excellent sales performance in overseas markets is a key factor for performance growth, attributed to the successful launch and promotion of products like the TrueForce® Pressure Monitoring RF Ablation Catheter and disposable star-shaped magnetic-electric mapping catheters abroad[8] - During the reporting period, the company's main business maintained a strong development trend, achieving steady growth in overall sales, which led to a significant year-on-year increase in net profit[8] Risk Warning and Other Notes The company confirms no major uncertainties affecting the forecast's accuracy but advises investors that the preliminary, unaudited data is subject to the final 2025 semi-annual report - The company states that there are no significant uncertainties affecting the accuracy of this performance forecast[9] - The company reminds investors that the forecast data is only preliminary, and the specific accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, urging caution regarding investment risks[10]